Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Preventive and Therapeutic Vaccines against HIV: From New Mechanisms to Clinical Trials

Yury Zhernov
* ORCID logo ,
Vladislava Petrova
,
Mark Simanduyev
,
Sonya Vysochanskaya
,
Inna Fadeeva
ORCID logo ,
Ksenja Riabova
,
Maria Zhuravleva
,
Denis Gorshenin
,
Artem Basov
ORCID logo ,
Denis Shcherbakov
,
Oleg Mitrokhin
ORCID logo
Version 1 : Received: 30 October 2023 / Approved: 31 October 2023 / Online: 31 October 2023 (06:13:14 CET)

How to cite: Zhernov, Y.; Petrova, V.; Simanduyev, M.; Vysochanskaya, S.; Fadeeva, I.; Riabova, K.; Zhuravleva, M.; Gorshenin, D.; Basov, A.; Shcherbakov, D.; Mitrokhin, O. Preventive and Therapeutic Vaccines against HIV: From New Mechanisms to Clinical Trials. Preprints 2023, 2023101996. https://doi.org/10.20944/preprints202310.1996.v1 Zhernov, Y.; Petrova, V.; Simanduyev, M.; Vysochanskaya, S.; Fadeeva, I.; Riabova, K.; Zhuravleva, M.; Gorshenin, D.; Basov, A.; Shcherbakov, D.; Mitrokhin, O. Preventive and Therapeutic Vaccines against HIV: From New Mechanisms to Clinical Trials. Preprints 2023, 2023101996. https://doi.org/10.20944/preprints202310.1996.v1

Abstract

As of the end of 2022, despite the disruptions caused by the COVID-19 pandemic, the global HIV epidemic persists, with 39 million individuals living with the virus and 1.3 million new infections reported in that year. Opportunistic infections associated with AIDS claimed the lives of over 630,000 people in 2022, contributing to a cumulative death toll exceeding 40.4 million since the disease's emergence in 1981. Although advances in HIV diagnosis and antiretroviral therapy have transformed the disease into a manageable chronic condition, issues like drug resistance, low compliance, and high treatment costs persist. Until a vaccine becomes available, a comprehensive approach involving prevention and therapy is essential, particularly for high-risk populations. Research shows that prevention strategies are more cost-effective than treatment. The development of antiretroviral drugs has also spurred the creation of antivirals for other infections. The emergence of COVID-19 vaccines has opened new avenues for HIV vaccine development, as lessons from vaccine platform technologies like mRNA, viral vectors, and protein subunits can be applied to HIV. This review explores the most promising prophylactic and therapeutic HIV vaccine trials, emphasizing the need for a multi-pronged approach combining vaccines with non-vaccine strategies. Though significant progress is anticipated, the road to a viable HIV vaccine remains long, especially for high-risk populations, such as medical workers, blood transfusion recipients, and drug users. The combinatorial approach, capitalizing on various aspects of immunity, may hold the key to defeating HIV in the future.

Keywords

HIV; preventive vaccines; therapeutic vaccines; AIDS; vaccine targets

Subject

Medicine and Pharmacology, Immunology and Allergy

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 1
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.